出 处:《中医学报》2020年第3期642-646,共5页Acta Chinese Medicine
基 金:河北省承德市科学技术与发展计划项目(201706A00).
摘 要:目的:探讨益脾正肝方联合经导管肝动脉栓塞化疗(transcatheter arterial chemoembolization,TACE)与热疗对中晚期原发性肝癌患者血清肿瘤标志物水平的影响。方法:84例中晚期原发性肝癌患者按照对治疗方式的接受程度分为对照组和治疗组。对照组40例患者给予TACE+热疗,治疗组44例患者给予益脾正肝方+TACE+热疗。治疗后比较两组患者血清肿瘤标志物水平[甲胎蛋白(alpha fetoprotein,AFP)、癌胚抗原(carcino-embryonic antigen,CEA)、组织多肽抗原(tissue polypeptide antigen,TPA)、糖链抗原199(carbohydrate antigen 199,CA199)、α-L-岩藻糖苷酶(a-L-fucosidase,AFU)]、肝功能[血清谷丙转氨酶(alanine transaminase,ALT)、谷草转氨酶(glutamic oxalacetic transaminase,AST)及总胆红素(total bilirubin,TBiL)]、卡氏评分(Karnofsky performance scoring,KPS)和中医证候积分,并评价治疗结果及不良反应。结果:治疗后治疗组患者血清AFP、AFU、CEA、CA199、TPA显著低于对照组(P<0.05),血清ALT、AST、TBiL水平显著低于对照组(P<0.05),中医证候积分显著低于对照组(P<0.05),KPS显著高于对照组(P<0.05),稳定率、有效率高于对照组(P<0.05)。两组WHO化疗不良反应分级比较,差异有统计学意义(P<0.05)。结论:益脾正肝方能显著减少中晚期原发性肝癌行TACE+热疗患者不良反应,改善临床症状,降低血清肿瘤标志物水平和肝损伤,提高生活质量。Objective:To investigate the effects of Yipizhenggan Prescription combined with transcatheter arterial chemoembolization(TACE)and hyperthermia on serum tumor markers in patients with intermediate and advanced primary liver cancer.Methods:84 patients with intermediate and advanced primary liver cancer were divided into control group and treatment group according to their acceptance of treatment.44 patients in the control group were given TACE+hyperthermia,and 40 patients in the treatment group were given Yipi Zhenggan Prescription+TACE+hyperthermia.After treatment,the levels of serum tumor markers[alpha fetoprotein(AFP),carcino-embryonic antigen(CEA),tissue polypeptide antigen(TPA),carbohydrate antigen 199(CA199),a-L-fucosidase(AFU)],liver function[serum alanine transaminase(ALT),glutamic oxalic transaminase(AST)and total bilirubin(TBiL)],Karnofsky s performance scoring(KPS)and TCM syndrome score were compared between the two groups,,as well as the treatment results and adverse reactions were evaluated.Results:After treatment,the levels of serum AFP,AFU,CEA,CA199 and TPA in the treatment group were significantly lower than those in the control group(P<0.05),the levels of serum ALT,AST and TBiL were significantly lower than those in the control group(P<0.05),the TCM syndrome score was significantly lower than that in the control group(P<0.05),the KPS score was significantly higher than that in the control group(P<0.05),and the stability rate and effective rate were higher than those in the control group(P<0.05).There was significant difference between the two groups(P<0.05).Conclusion:Yipi Zhenggan Prescription can significantly reduce adverse reactions in patients with TACE+hyperthermia of intermediate and advanced primary liver cancer,improve clinical symptoms,reduce serum tumor marker levels and liver damage,and improve quality of life.
关 键 词:原发性肝癌 益脾正肝方 经导管肝动脉栓塞化疗 热疗 肿瘤标志物 中西医结合
分 类 号:R273.357[医药卫生—中西医结合]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...